세계의 Drug Discovery 서비스 시장 예측(-2030년) : 프로세스별, 유형별, 치료 영역별, 약제 유형별, 최종사용자별, 지역별

The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%. The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users.

"Chemistry services dominated the type segment"

Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry's extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.

"The hit-to-lead identification dominated the process segment"

Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.

"The small molecules dominated the drug type segment"

Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.

"Cardiovascular diseases segment is anticipated to grow at a great pace"

The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.

"Pharmaceutical & Biotechnology Companies dominated the segment"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.

"US to grow at the highest CAGR for North America drug discovery services market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country's focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Directors - 45%, Managers - 30%, and Others - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), Evotec (Germany), Syngene International Limited (India), Curia Global, Inc. (US), Aragen Life Sciences Ltd. (India), Jubilant Pharmova Limited (India), Dr. Reddy's Laboratories Ltd. (India), Frontage Holdings Corporation (US), GenScript (US), Sygnature Discovery (UK), and Piramal Enterprises Ltd. (India) are some of the key players in the drug discovery services market.

Research Coverage:

Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 SEGMENTAL MARKET ESTIMATION
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
• 4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY, 2024
• 4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Booming research & development expenditure in pharma-biotech sector
    • 5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies
    • 5.2.1.3 Rising research on rare diseases and orphan drugs
    • 5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulations
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements and new drug discovery techniques
    • 5.2.3.2 Rising demand for specialized testing services
    • 5.2.3.3 Patent expiry of key biologics
    • 5.2.3.4 High growth prospects in emerging markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Economic uncertainties worldwide
  • 5.2.5 MARKET TRENDS
    • 5.2.5.1 Adoption of AI in drug discovery
    • 5.2.5.2 Increased outsourcing in emerging economies
    • 5.2.5.3 Consolidation of contract research organizations
    • 5.2.5.4 Integrated end-to-end R&D service offerings
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
  • 5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 High-throughput screening
    • 5.9.1.2 CRISPR gene editing
    • 5.9.1.3 Structure-based drug design/Computer-aided drug design
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Automated liquid handling
    • 5.9.2.2 In silico modeling
    • 5.9.2.3 Patient-derived xenografts and organoids
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Nanotechnology
    • 5.9.3.2 Synthetic biology
    • 5.9.3.3 Organ-on-a-chip technology
• 5.10 PATENT ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY FRAMEWORK
    • 5.12.1.1 North America
      • 5.12.1.1.1 US
      • 5.12.1.1.2 Canada
    • 5.12.1.2 Europe
      • 5.12.1.2.1 UK
    • 5.12.1.3 Asia Pacific
      • 5.12.1.3.1 China
      • 5.12.1.3.2 Japan
      • 5.12.1.3.3 India
      • 5.12.1.3.4 South Korea
      • 5.12.1.3.5 Australia
      • 5.12.1.3.6 Rest of Asia Pacific
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 BARGAINING POWER OF SUPPLIERS
  • 5.13.2 BARGAINING POWER OF BUYERS
  • 5.13.3 THREAT OF NEW ENTRANTS
  • 5.13.4 THREAT OF SUBSTITUTES
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA, BY END USER
• 5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
  • 5.15.3 AI USE CASES
  • 5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

• 6.1 INTRODUCTION
• 6.2 TARGET SELECTION
  • 6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
• 6.3 TARGET VALIDATION
  • 6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
• 6.4 HIT-TO-LEAD IDENTIFICATION
  • 6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
• 6.5 LEAD OPTIMIZATION
  • 6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
• 6.6 CANDIDATE VALIDATION
  • 6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 CHEMISTRY SERVICES
  • 7.2.1 SYNTHETIC CHEMISTRY SERVICES
    • 7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth
  • 7.2.2 ANALYTICAL CHEMISTRY SERVICES
    • 7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth
  • 7.2.3 OTHER CHEMISTRY SERVICES
• 7.3 BIOLOGY SERVICES
  • 7.3.1 IN VITRO PROFILING SERVICES
    • 7.3.1.1 Need for higher project productivity to speed up growth
  • 7.3.2 TOXICOLOGY SERVICES
    • 7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market
  • 7.3.3 OTHER BIOLOGY SERVICES

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

• 8.1 INTRODUCTION
• 8.2 SMALL MOLECULES
  • 8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
• 8.3 BIOLOGICS
  • 8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 ONCOLOGY
  • 9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
• 9.3 INFECTIOUS DISEASES
  • 9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
• 9.4 CARDIOVASCULAR DISEASES
  • 9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH
• 9.5 NEUROLOGICAL DISEASES
  • 9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
• 9.6 IMMUNOLOGICAL DISORDERS
  • 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
• 9.7 ENDOCRINE & METABOLIC DISORDERS
  • 9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH
• 9.8 RESPIRATORY DISORDERS
  • 9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
• 9.9 DIGESTIVE SYSTEM DISEASES
  • 9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
• 9.10 GENITOURINARY DISEASES & WOMEN'S HEALTH
  • 9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
• 9.11 OTHER THERAPEUTIC AREAS

10 DRUG DISCOVERY SERVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 TIER 1 COMPANIES
    • 10.2.1.1 Rising research & development activities to sustain growth
  • 10.2.2 TIER 2 COMPANIES
    • 10.2.2.1 Growing focus on specific therapeutic areas to drive market
  • 10.2.3 TIER 3 COMPANIES
    • 10.2.3.1 Increasing specialized drug discovery projects to expedite growth
• 10.3 ACADEMIC INSTITUTES
  • 10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
• 10.4 OTHER END USERS

11 DRUG DISCOVERY SERVICES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK OF EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising dominance of contract research organizations to encourage growth
  • 11.3.3 UK
    • 11.3.3.1 Increasing government-private sector collaborations to boost market
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing number of oncology research projects to propel market
  • 11.3.5 ITALY
    • 11.3.5.1 High number of clinical trials and low drug approval time to promote growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising elderly population to intensify growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Booming pharmaceutical industry to sustain growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing geriatric population to support growth
  • 11.4.4 INDIA
    • 11.4.4.1 Growing foreign direct investments to drive market
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Favorable government support to accelerate growth
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Rising number of clinical trials to foster growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Reduced timeline for drug approvals to favor growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Favorable government policies to intensify growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Booming healthcare expenditure to contribute to growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth
    • 11.6.2.3 Other GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/SERVICE COMPARISON
  • 12.6.1 THERMO FISHER SCIENTIFIC INC. (US)
  • 12.6.2 CHARLES RIVER LABORATORIES (US)
  • 12.6.3 LABCORP (US)
  • 12.6.4 WUXI APPTEC (CHINA)
  • 12.6.5 PHARMARON (CHINA)
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Process footprint
    • 12.7.5.4 Type footprint
    • 12.7.5.5 Therapeutic area footprint
    • 12.7.5.6 Drug type footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 SERVICE LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Service launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 CHARLES RIVER LABORATORIES
    • 13.1.2.1 Business overview
    • 13.1.2.2 Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Service launches
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 WUXI APPTEC
    • 13.1.3.1 Business overview
    • 13.1.3.2 Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 PHARMARON
    • 13.1.4.1 Business overview
    • 13.1.4.2 Services offered
      • 13.1.4.2.1 Deals
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses and competitive threats
  • 13.1.5 LABCORP
    • 13.1.5.1 Business overview
    • 13.1.5.2 Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 EVOTEC
    • 13.1.6.1 Business overview
    • 13.1.6.2 Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
      • 13.1.6.3.2 Expansions
      • 13.1.6.3.3 Other developments
  • 13.1.7 SYNGENE INTERNATIONAL LIMITED
    • 13.1.7.1 Business overview
    • 13.1.7.2 Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
      • 13.1.7.3.2 Expansions
  • 13.1.8 EUROFINS SCIENTIFIC
    • 13.1.8.1 Business overview
    • 13.1.8.2 Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Service launches
      • 13.1.8.3.2 Deals
      • 13.1.8.3.3 Expansions
  • 13.1.9 JUBILANT PHARMOVA LIMITED
    • 13.1.9.1 Business overview
    • 13.1.9.2 Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
      • 13.1.9.3.2 Expansions
  • 13.1.10 GENSCRIPT
    • 13.1.10.1 Business overview
    • 13.1.10.2 Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Service launches
      • 13.1.10.3.2 Deals
  • 13.1.11 FRONTAGE HOLDINGS CORPORATION
    • 13.1.11.1 Business overview
    • 13.1.11.2 Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Service launches
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Expansions
  • 13.1.12 PIRAMAL ENTERPRISES LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Expansions
  • 13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Service launches
      • 13.1.13.3.2 Deals
      • 13.1.13.3.3 Expansions
  • 13.1.14 CURIA GLOBAL, INC.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Service launches
      • 13.1.14.3.2 Deals
      • 13.1.14.3.3 Other developments
  • 13.1.15 SHANGHAI MEDICILON INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
      • 13.1.15.3.2 Expansions
  • 13.1.16 SYGNATURE DISCOVERY
    • 13.1.16.1 Business overview
    • 13.1.16.2 Services offered
      • 13.1.16.2.1 Deals
      • 13.1.16.2.2 Expansions
• 13.2 OTHER PLAYERS
  • 13.2.1 SELVITA
  • 13.2.2 VIVA BIOTECH
  • 13.2.3 TCG LIFESCIENCES PVT. LTD.
  • 13.2.4 SHANGHAI CHEMPARTNER
  • 13.2.5 DOMAINEX
  • 13.2.6 NUVISAN GMBH
  • 13.2.7 DALTON PHARMA SERVICES
  • 13.2.8 ARAGEN LIFE SCIENCES LTD.
  • 13.2.9 ONCODESIGN SERVICES

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS